Supplemental HIV Testing Market Woes Force FDA To Consider Other Options
This article was originally published in The Gray Sheet
Executive Summary
The financial instability of Calypte Biomedical over the past several months has increased FDA's interest in licensing alternative approaches for confirmatory HIV testing for blood banks, including nucleic acid testing
You may also be interested in...
HIV test shortage
Calypte Biomedical's April announcement of possible bankruptcy triggers CDC's May 10 warning of potential U.S. shortage of supplemental tests kits for confirmatory testing of HIV antibodies in specimens derived from patients or blood donors. Distributor bioMérieux has notified customers of a halt in Cambridge Biotech HIV-1 Western blot kit shipments. CDC and FDA have contacted other HIV test-makers, including BioRad Laboratories and OraSure, about ramping up kit production. Labs experiencing shortage should contact CDC at 404-639-4581...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.